Cantor Fitzgerald Brokers Raise Earnings Estimates for HRMY

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Harmony Biosciences in a research note issued on Wednesday, May 7th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of $2.68 for the year, up from their previous estimate of $2.43. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS.

Several other analysts have also commented on HRMY. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target for the company. Mizuho increased their target price on Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday, March 18th. Finally, UBS Group lowered their price objective on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, April 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $52.33.

Harmony Biosciences Trading Down 0.1 %

Shares of Harmony Biosciences stock opened at $34.05 on Friday. Harmony Biosciences has a 1-year low of $26.47 and a 1-year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock’s 50 day simple moving average is $31.38 and its 200-day simple moving average is $34.01. The stock has a market cap of $1.96 billion, a P/E ratio of 16.14, a P/E/G ratio of 0.47 and a beta of 0.82.

Institutional Trading of Harmony Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Hillsdale Investment Management Inc. lifted its stake in shares of Harmony Biosciences by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after purchasing an additional 300 shares during the period. Aurora Investment Counsel raised its position in shares of Harmony Biosciences by 0.6% in the first quarter. Aurora Investment Counsel now owns 61,667 shares of the company’s stock valued at $2,047,000 after buying an additional 374 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock valued at $704,000 after buying an additional 420 shares during the period. GAMMA Investing LLC grew its stake in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the period. Finally, Rhumbline Advisers raised its holdings in Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock valued at $3,620,000 after acquiring an additional 485 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.